Skip to main content
. 2009 Mar 12;47(1):1–5. doi: 10.3347/kjp.2009.47.1.1

Fig. 5.

Fig. 5

Variations in the prevalence in humans with 2 control measures. 1: Yearly universal treatment (UT) with a 70% coverage rate for the initial 3 years (solid line), 2: After 3 years of annual UT targeted mass treatment (TT) with a 85% coverage rate (dashed line) [14].